Evaluation of Different Treatment Modules for Respiratory Distress Syndrome in Preterm Neonates
Different Treatment Modules for Respiratory Distress Syndrome
Background: RDS is mainly caused by a lack of a slippery substance in the lungs called surfactant. This substance helps the lungs fill with air and keeps the air sacs from deflating. Present study is to assess the difference between intravenous and inhalational ambroxol in prevention of respiratory distress syndrome in preterm infants. Subjects and Methods: Out of those 56 were assigned under group A i.e. being treated with intravenous ambroxol and others were assigned under group B i.e. being treated by atomizing or inhalational ambroxol. The intravenous group was injected with 15mg/kg ambroxol in umbilical vein immediately after birth followed by intravenous infusion of ambroxol 30mg/kg for 2 days. Results: Early administration of either intravenous or atomizing ambroxol can produce a positive efficacy for the prevention of RDS in preterm infants but inhalation or atomizing has better outcomes as compared to intravenous ambroxol. Conclusion: There are good results of aerosolized ambroxol in the management of RDS and it is the easy, economic and ideal treatment module for RDS.